603739 蔚蓝生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1553.9663.6354.8144.299
总资产报酬率 ROA (%)1.2742.3192.0832.8762.910
投入资产回报率 ROIC (%)1.5522.8622.5823.4813.455

边际利润分析
销售毛利率 (%)43.91444.79645.04646.22743.231
营业利润率 (%)9.7639.3409.39010.2518.847
息税前利润/营业总收入 (%)11.07810.44210.91911.4009.239
净利润/营业总收入 (%)7.5177.1346.9798.5797.343

收益指标分析
经营活动净收益/利润总额(%)76.05068.63880.00085.72486.406
价值变动净收益/利润总额(%)10.44325.3135.73412.7653.406
营业外收支净额/利润总额(%)-0.641-3.141-0.470-0.331-0.701

偿债能力分析
流动比率 (X)1.2361.1701.0371.0331.503
速动比率 (X)0.9940.9460.8530.8441.234
资产负债率 (%)36.71337.14037.26939.83732.764
带息债务/全部投入资本 (%)25.65625.60724.84027.95422.397
股东权益/带息债务 (%)281.107280.744291.569249.206336.089
股东权益/负债合计 (%)162.187157.893156.413141.336194.654
利息保障倍数 (X)8.0487.5326.9429.63720.368

营运能力分析
应收账款周转天数 (天)100.11996.11191.74293.28484.607
存货周转天数 (天)106.10999.12897.800105.83090.137